|
| Exchange Disseminated Time 25/09/2018 16:13:07 | | Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of Glenmark Pharmaceuticals Limited (“Company”) will be held on September 28, 2018, to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million 2 per cent resettable onward starting equity linked securities due June 28, 2022 issued in 2016 (“FCC Bonds”) and / or, its U.S.$200 million 4.5% senior notes due 2021 issued in 2016 (“FCY Bonds”), based on market opportunities and conditions from time to time and to delegate powers to operations committee. The Operations Committee, based on market opportunities and conditions, will hold meetings during the next one month to consider and approve the terms and conditions of any tenders or buybacks. |
|
|